United Therapeutics (NASDAQ:UTHR) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.

Several other research firms have also weighed in on UTHR. Wedbush restated an “outperform” rating and set a $232.00 price objective (up from $213.00) on shares of United Therapeutics in a research note on Wednesday, December 27th. ValuEngine upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 26th. Oppenheimer boosted their price objective on shares of United Therapeutics to $180.00 and gave the stock an “outperform” rating in a research note on Friday, January 5th. Zacks Investment Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 price objective on the stock in a research note on Monday. Finally, TheStreet upgraded shares of United Therapeutics from a “c+” rating to a “b” rating in a research note on Friday, December 15th. Four analysts have rated the stock with a sell rating, six have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. United Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $140.45.

United Therapeutics (UTHR) traded down $6.15 during trading on Tuesday, hitting $135.12. 627,905 shares of the stock traded hands, compared to its average volume of 399,880. The firm has a market cap of $5,890.00, a price-to-earnings ratio of 11.92 and a beta of 1.41. United Therapeutics has a one year low of $112.01 and a one year high of $169.89.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, topping the consensus estimate of $4.01 by $2.26. The company had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. United Therapeutics’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the previous year, the business earned $4.23 EPS. equities research analysts predict that United Therapeutics will post 12.96 EPS for the current year.

In other United Therapeutics news, CEO Martine A. Rothblatt sold 1,263 shares of the business’s stock in a transaction dated Thursday, October 26th. The shares were sold at an average price of $120.38, for a total value of $152,039.94. Following the completion of the sale, the chief executive officer now owns 1,403 shares of the company’s stock, valued at approximately $168,893.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 1,265 shares of the business’s stock in a transaction dated Thursday, October 19th. The shares were sold at an average price of $119.38, for a total transaction of $151,015.70. Following the completion of the sale, the chief executive officer now directly owns 1,405 shares of the company’s stock, valued at approximately $167,728.90. The disclosure for this sale can be found here. Insiders have sold a total of 15,773 shares of company stock valued at $1,925,637 in the last ninety days. 7.80% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. BlackRock Inc. boosted its holdings in United Therapeutics by 4,222.8% in the 1st quarter. BlackRock Inc. now owns 4,741,985 shares of the biotechnology company’s stock valued at $641,969,000 after purchasing an additional 4,632,287 shares during the period. Scopia Capital Management LP bought a new stake in shares of United Therapeutics during the 3rd quarter worth approximately $483,266,000. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of United Therapeutics during the 4th quarter worth approximately $102,341,000. LSV Asset Management lifted its holdings in shares of United Therapeutics by 575.5% during the 4th quarter. LSV Asset Management now owns 704,455 shares of the biotechnology company’s stock worth $110,324,000 after acquiring an additional 600,162 shares during the period. Finally, Emerald Acquisition Ltd. bought a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $47,352,000.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/16/united-therapeutics-uthr-downgraded-to-sell-at-bidaskclub.html.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.